Igor I. Rybkin

3.7k citations

41 papers · 1.8k · 2 hit papers · h-index 17

Impact in

Behavioral Neuroscience top 5%
- Stress Responses and Cortisol
Endocrine and Autonomic Systems top 5%

Papers in

Oncology 22
- Cancer Immunotherapy and Biomarkers 7
- Colorectal Cancer Treatments and Studies 6
- Pancreatic and Hepatic Oncology Research 4
- Peptidase Inhibition and Analysis 4
Molecular Biology 15

Co-authors: Gennady Smagin (2 shared papers)Ruth B.S. Harris (2 shared papers)Donna H. Ryan (2 shared papers)Rhonda Bassel‐Duby (4 shared papers)John M. Shelton (2 shared papers)Melissa L. Johnson (6 shared papers)Minal Barve (6 shared papers)James G. Christensen (8 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Journal of Thoracic Oncology (8 papers)Annals of Oncology (5 papers)International Journal of Radiation Oncology*Biology*Physics (4 papers)Journal of Biological Chemistry (2 papers)
Partner nations: United States Netherlands Italy

In The Last Decade

Igor I. Rybkin

40 papers receiving 1.8k citations

Igor I. Rybkin's Hit Papers

align trajectories log scale

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1) 2022 · 221 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Oncology
2005 Cell Metabolism

Peers

Countries citing papers authored by Igor I. Rybkin

Since Specialization

Citations

This map shows the geographic impact of Igor I. Rybkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor I. Rybkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor I. Rybkin more than expected).

Fields of papers citing papers by Igor I. Rybkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor I. Rybkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor I. Rybkin. The network helps show where Igor I. Rybkin may publish in the future.

Co-authors

The 25 scholars most cited alongside Igor I. Rybkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Igor I. Rybkin Line = papers co-authored together Igor I. Rybkin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle Cell Metabolism ·Zoltàn Arany, Huamei He, Jiandie D. Lin, Kirsten Hoyer, Christoph Handschin, Okan Toka, Ferhaan Ahmad, Takashi Matsui, Sherry Chin, Pei-Hsuan Wu, Igor I. Rybkin, John M. Shelton, Monia Manieri, Saverio Cinti, Frederick J. Schöen, Rhonda Bassel‐Duby, Anthony Rosenzweig, Joanne S. Ingwall, Bruce M. Spiegelman Hit paper breakdown →	2005	574
2	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^G12C Solid Tumors (KRYSTAL-1) Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Pasi A. Jänne, Ticiana Leal, Igor I. Rybkin, Joshua K. Sabari, Minal Barve, Lyudmila Bazhenova, Melissa L. Johnson, Karen Velastegui, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos Hit paper breakdown →	2022	221
3	Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ·Ruth B.S. Harris, Jun Zhou, Bradley D. Youngblood, Igor I. Rybkin, Gennady Smagin, Donna H. Ryan	1998	181
4	Effect of restraint stress on food intake and body weight is determined by time of day American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ·Igor I. Rybkin, You Zhou, Júlia Vólaufová, Gennady Smagin, Donna H. Ryan, Ruth B.S. Harris	1997	160
5	KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation European Journal of Cancer ·Pasi A. Jänne, Igor I. Rybkin, Alexander I. Spira, Gregory J. Riely, K. Papadopoulos, Joshua K. Sabari, Melissa L. Johnson, Rebecca S. Heist, Lyudmila Bazhenova, Minal Barve, J.M. Pacheco, Ticiana Leal, Karen Velastegui, Crystal Cornelius, Peter Olson, James G. Christensen, Thian Kheoh, Richard C. Chao, S.‐H.I. Ou	2020	105
6	Calcineurin Is Necessary for the Maintenance but Not Embryonic Development of Slow Muscle Fibers Molecular and Cellular Biology ·Misook Oh, Igor I. Rybkin, Victoria Copeland, Michael P. Czubryt, John M. Shelton, Eva van Rooij, James A. Richardson, Joseph A. Hill, León J. De Windt, Rhonda Bassel‐Duby, Eric N. Olson, Beverly A. Rothermel	2005	80
7	99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation Journal of Thoracic Oncology ·G.J. Riely, S-H.I. Ou, Igor I. Rybkin, Alexander I. Spira, K. Papadopoulos, Joshua K. Sabari, Melissa L. Johnson, Rebecca S. Heist, Lyudmila Bazhenova, Minal Barve, J.M. Pacheco, Karen Velastegui, Cornelius Cilliers, Peter Olson, James G. Christensen, Thian Kheoh, Richard C. Chao, P.A. Jänne	2021	58
8	KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS^G12C mutation. Journal of Clinical Oncology ·Tanios Bekaii‐Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn J. McRee, Joshua K. Sabari, Melissa L. Johnson, Minal Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der‐Torossian, Igor I. Rybkin	2022	55
9	KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation European Journal of Cancer ·Melissa L. Johnson, S.-H.I. Ou, Minal Barve, Igor I. Rybkin, Kyriakos P. Papadopoulos, Ticiana Leal, Karen Velastegui, James G. Christensen, Thian Kheoh, Richard C. Chao, J. Weiß	2020	52
10	Conditional Expression of SV40 T-antigen in Mouse Cardiomyocytes Facilitates an Inducible Switch from Proliferation to Differentiation Journal of Biological Chemistry ·Igor I. Rybkin, David W. Markham, Zhen Yan, Rhonda Bassel‐Duby, R. Sanders Williams, Eric N. Olson	2003	40
11	Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) Journal of Thoracic Oncology ·David R. Spigel, Robert M. Jotte, John Nemunaitis, M. Shum, Jeffrey Schneider, Jerome H. Goldschmidt, Jennifer Eisenstein, David Berz, Lasika Seneviratne, Matei P. Socoteanu, Viralkumar K. Bhanderi, Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin	2020	38
12	Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours Annals of Oncology ·Aung Naing, Todd M. Bauer, K. Papadopoulos, Osama E. Rahma, Frank Tsai, Elena Garralda, Jarushka Naidoo, Sachin Gopalkrishna Pai, Michael K. Gibson, Igor I. Rybkin, Dee Dee Wang, David F. McDermott, Angelica Fasolo, (unknown), M. Shaheen, Yonchu Jenkins, Howard Kallender, Sven Gogov, Emil Kuriakose, Michael J. Pishvaian	2019	34
13	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer International Journal of Radiation OncologyBiologyPhysics ·Arya Amini, Vivek Verma, Charles B. Simone, Indrin J. Chetty, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Igor I. Rybkin, Ben J. Slotman, Andrea Wolf, Joe Y. Chang	2021	30
14	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC JTO Clinical and Research Reports ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Eric Angevin, David S. Hong, Igor I. Rybkin, Minal Barve, Todd M. Bauer, Angelo Delmonte, Martin Dunbar, Monica Motwani, Apurvasena Parikh, Elysa Noon, Jun Wu, Vincent Blot, Karen Kelly	2021	22
15	α1A Adrenergic Receptor Induces Eukaryotic Initiation Factor 4E-binding Protein 1 Phosphorylation via a Ca2+-dependent Pathway Independent of Phosphatidylinositol 3-kinase/Akt Journal of Biological Chemistry ·Igor I. Rybkin, Michael Cross, E.Michael McReynolds, Richard Z. Lin, Lisa M. Ballou	2000	21
16	Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. Journal of Clinical Oncology ·Lauren A. Byers, Kathryn A. Gold, Julio A. Peguero, Melissa L. Johnson, Jorgé Nieva, Wael A. Harb, Alberto Chiappori, Igor I. Rybkin, James Strauss, David E. Gerber	2021	17
17	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC Journal of Thoracic Oncology ·Kristin Higgins, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Stephen G. Chun, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. Chang	2020	16
18	1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Annals of Oncology ·Ticiana Leal, David Berz, Igor I. Rybkin, Wade T. Iams, Débora S. Bruno, Collin M. Blakely, Alexander I. Spira, Manish R. Patel, David Waterhouse, Donald Richards, Anthony Pham, Robert M. Jotte, Edward B. Garon, David S. Hong, Ronald Shazer, Xin Yan, L. Latven, Kai He	2021	15
19	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020 Journal of Thoracic Oncology ·Stephen G. Chun, Charles B. Simone, Arya Amini, Indrin J. Chetty, Jessica Donington, Martin J. Edelman, Kristin Higgins, Larry L. Kestin, Benjamin Movsas, George Rodrigues, Kenneth E. Rosenzweig, Ben J. Slotman, Igor I. Rybkin, Andrea Wolf, Joe Y. Chang	2020	15
20	Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. Journal of Clinical Oncology ·Leena Gandhi, Pasi A. Jänne, Mateusz Opyrchal, Suresh S. Ramalingam, Igor I. Rybkin, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich, Fang Wang, Peter Ordentlich, Susan Brouwer, Serap Sankoh, Emmett V. Schmidt, Michael L. Meyers, Matthew D. Hellmann	2018	15

About Igor I. Rybkin

Igor I. Rybkin is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 41 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Diagnosis and Treatment (6 papers), Colorectal Cancer Treatments and Studies (6 papers), Pancreatic and Hepatic Oncology Research (4 papers), Peptidase Inhibition and Analysis (4 papers), Phagocytosis and Immune Regulation (4 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Behavioral Neuroscience (159 citations), Endocrine and Autonomic Systems (126 citations), Physiology (448 citations), Oncology (431 citations) and Biological Psychiatry (29 citations). Igor I. Rybkin has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Gennady Smagin, Ruth B.S. Harris, Donna H. Ryan, Rhonda Bassel‐Duby, John M. Shelton, Melissa L. Johnson, Minal Barve, James G. Christensen, Karen Velastegui and Jiandie D. Lin. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Igor I. Rybkin

Impact in

Papers in i

In The Last Decade

Igor I. Rybkin

Igor I. Rybkin's Hit Papers

Peers

Countries citing papers authored by Igor I. Rybkin

Fields of papers citing papers by Igor I. Rybkin

All Works

About Igor I. Rybkin

Explore authors with similar magnitude of impact

Papers in